{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:18:49Z","timestamp":1778516329250,"version":"3.51.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"(Australian) National Health and Medical Research Council Investigator Grant","award":["1176131"],"award-info":[{"award-number":["1176131"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Implementation Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Deimplementation, the removal or reduction of potentially hazardous approaches to care, is key to progressing social equity in health. While the benefits of opioid agonist treatment (OAT) are well-evidenced, wide variability in the provision of treatment attenuates positive outcomes. During the COVID-19 pandemic, OAT services deimplemented aspects of provision which had long been central to treatment in Australia; supervised dosing, urine drug screening, and frequent in-person attendance for review. This analysis explored how providers considered social inequity in health of patients in the deimplementation of restrictive OAT provision during the COVID-19 pandemic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Between August and December 2020, semi-structured interviews were conducted with 29 OAT providers in Australia. Codes relating to the social determinants of client retention in OAT were clustered according to how providers considered deimplementation in relation to social inequities. Normalisation Process Theory was then used to analyse the clusters in relation to how providers understood their work during the COVID-19 pandemic as responding to systemic issues that condition OAT access.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We explored four overarching themes based on constructs from Normalisation Process Theory: adaptive execution, cognitive participation, normative restructuring, and sustainment. Accounts of adaptive execution demonstrated tensions between providers\u2019 conceptions of equity and patient autonomy. Cognitive participation and normative restructuring were integral to the workability of rapid and drastic changes within the OAT services. Key transformative actors included communities of practice and \u201cthought leaders\u201d who had long supported deimplementation for more humane care. At this early stage of the pandemic, providers had already begun to consider how this period could inform sustainment of deimplementation. When considering a future, post-pandemic period, several providers expressed discomfort at operating with \u201cevidence-enough\u201d and called for narrowly defined types of data on adverse events (e.g. overdose) and expert consensus on takeaway doses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The possibilities for achieving social equity in health are limited by the divergent treatment goals of providers and people receiving OAT. Sustained and equitable deimplementation of obtrusive aspects of OAT provision require co-created treatment goals, patient-centred monitoring and evaluation, and access to a supportive community of practice for providers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13012-023-01281-4","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T07:02:03Z","timestamp":1686294123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Deimplementation in the provision of opioid agonist treatment to achieve equity of care for people engaged in treatment: a qualitative study"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-9714","authenticated-orcid":false,"given":"Anna","family":"Conway","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison D.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sione","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Hayllar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Grebely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Treloar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"1281_CR1","first-page":"80","volume":"1","author":"A Ivsins","year":"2020","unstructured":"Ivsins A, Boyd J, Beletsky L, McNeil R. Tackling the overdose crisis: the role of safe supply. Int J Drug Policy. 2020;1:80.","journal-title":"Int J Drug Policy"},{"issue":"7879","key":"1281_CR2","first-page":"1","volume":"345","author":"GJ MacArthur","year":"2012","unstructured":"MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ Online. 2012;345(7879):1\u201316.","journal-title":"BMJ Online"},{"key":"1281_CR3","doi-asserted-by":"crossref","unstructured":"Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2017;113(3):545\u201363.","DOI":"10.1111\/add.14012"},{"key":"1281_CR4","doi-asserted-by":"crossref","unstructured":"Santo TJ, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence a systematic review and meta-analysis. JAMA Psychiatry. 2021;1;78(9):979\u201393.","DOI":"10.1001\/jamapsychiatry.2021.0976"},{"issue":"3","key":"1281_CR5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/add.13622","volume":"112","author":"RP Schwartz","year":"2017","unstructured":"Schwartz RP, Kelly SM, Mitchell SG, Gryczynski J, O\u2019Grady KE, Gandhi D, et al. Patient-centered methadone treatment: a randomized clinical trial: patient-centered methadone. Addiction. 2017;112(3):454\u201364.","journal-title":"Addiction"},{"issue":"64","key":"1281_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drugpo.2018.08.006","volume":"1","author":"J McEachern","year":"2019","unstructured":"McEachern J, Adye-White L, Priest KC, Moss E, Gorfinkel L, Wood E, et al. Lacking evidence for the association between frequent urine drug screening and health outcomes of persons on opioid agonist therapy. Int J Drug Policy. 2019;1(64):30\u20133.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1281_CR7","first-page":"CD011983","volume":"2017","author":"R Saulle","year":"2017","unstructured":"Saulle R, Vecchi S, Gowing L. Supervised dosing with a long-acting opioid medication in the management of opioid dependence. Cochrane Database Syst Rev. 2017;2017(4):CD011983.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1281_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/09687630600997527","volume":"14","author":"C Treloar","year":"2007","unstructured":"Treloar C, Fraser S, Valentine K. Valuing methadone takeaway doses: the contribution of service-user perspectives to policy and practice. Drugs Educ Prev Policy. 2007;14(1):61\u201374.","journal-title":"Drugs Educ Prev Policy"},{"issue":"1","key":"1281_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-021-00535-y","volume":"18","author":"D Frank","year":"2021","unstructured":"Frank D, Mateu-Gelabert P, Perlman DC, Walters SM, Curran L, Guarino H. \u201cIt\u2019s like \u2018liquid handcuffs\u201d: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives. Harm Reduct J. 2021;18(1):1\u201310.","journal-title":"Harm Reduct J"},{"key":"1281_CR10","volume-title":"Opioid Agonist Therapy in Australia: A History","author":"R Nicholas","year":"2022","unstructured":"Nicholas R. Opioid Agonist Therapy in Australia: A History. Adelaide: National Centre for Education and Training on Addiction (NCETA), Flinders University; 2022."},{"key":"1281_CR11","unstructured":"Australian Institute of Health and Welfare. National Opioid Pharmacotherapy Statistics Annual Data collection. 2022. Available from: https:\/\/www.aihw.gov.au\/reports\/alcohol-other-drug-treatment-services\/national-opioid-pharmacotherapy-statistics-2019\/contents\/clients. [Cited 2022 Jul 6]."},{"key":"1281_CR12","doi-asserted-by":"publisher","first-page":"103472","DOI":"10.1016\/j.drugpo.2021.103472","volume":"99","author":"AD Tran","year":"2022","unstructured":"Tran AD, Chen R, Nielsen S, Zahra E, Degenhardt L, Santo T, et al. Economic analysis of out-of-pocket costs among people in opioid agonist treatment\u202f: a cross-sectional survey in three Australian jurisdictions. Int J Drug Policy. 2022;99:103472.","journal-title":"Int J Drug Policy"},{"key":"1281_CR13","volume-title":"Coronavirus Pandemic (COVID-19)","author":"H Ritchie","year":"2020","unstructured":"Ritchie H, Mathieu E, Rod\u00e9s-Guirao L, Appel C, Ortiz-Ospina E, et al. Coronavirus Pandemic (COVID-19). 2020. Available from: OurWorldInData.org. [Cited 2022 May 25]."},{"key":"1281_CR14","unstructured":"Department of Education Skills and Employment. ECEC COVID-19 timeline. 2021. Available from: https:\/\/www.dese.gov.au\/covid-19\/resources\/ecec-covid19-timeline. [Cited 2022 May 25]."},{"issue":"9","key":"1281_CR15","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1001\/jama.2022.1271","volume":"327","author":"T Gomes","year":"2022","unstructured":"Gomes T, Campbell TJ, Kitchen SA, Garg R, Bozinoff N, Men S, et al. Association between increased dispensing of opioid agonist therapy take-home doses and opioid overdose and treatment interruption and discontinuation. JAMA - J Am Med Assoc. 2022;327(9):846\u201355.","journal-title":"JAMA - J Am Med Assoc"},{"key":"1281_CR16","doi-asserted-by":"crossref","unstructured":"Jones CM, Compton WM, Han B, Baldwin G, Volkow ND. Methadone-involved overdose deaths in the US before and after federal policy changes expanding take-home methadone doses from opioid treatment programs. JAMA Psychiatry. 2022. Available from: https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2793744. [Cited 2022 Jul 22].","DOI":"10.1001\/jamapsychiatry.2022.1776"},{"key":"1281_CR17","doi-asserted-by":"publisher","first-page":"108164","DOI":"10.1016\/j.jsat.2020.108164","volume":"121","author":"A Meteliuk","year":"2021","unstructured":"Meteliuk A, Galvez de Leon SJ, Madden LM, Pykalo I, Fomenko T, Filippovych M, et al. Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine. J Subst Abuse Treat. 2021;121:108164.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"1281_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13643-019-1111-8","volume":"8","author":"C Burton","year":"2019","unstructured":"Burton C, Williams L, Bucknall T, Edwards S, Fisher D, Hall B, et al. Understanding how and why de-implementation works in health and care: research protocol for a realist synthesis of evidence. Syst Rev. 2019;8(1):194.","journal-title":"Syst Rev"},{"issue":"1","key":"1281_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13012-019-0960-9","volume":"15","author":"WE Norton","year":"2020","unstructured":"Norton WE, Chambers DA. Unpacking the complexities of de-implementing inappropriate health interventions. Implement Sci. 2020;15(1):2.","journal-title":"Implement Sci"},{"issue":"29","key":"1281_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.18865\/ed.29.S1.93","volume":"1","author":"CD Helfrich","year":"2019","unstructured":"Helfrich CD, Hartmann CW, Parikh TJ, Au DH. Promoting health equity through de-implementation research. Ethn Dis. 2019;1(29):93\u20136.","journal-title":"Ethn Dis"},{"issue":"35","key":"1281_CR21","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1007\/s11606-020-06254-7","volume":"1","author":"SG Kertesz","year":"2020","unstructured":"Kertesz SG, McCullough MB, Darnall BD, Varley AL. Promoting patient-centeredness in opioid deprescribing: a blueprint for de-implementation science. J Gen Intern Med. 2020;1(35):972\u20137.","journal-title":"J Gen Intern Med"},{"key":"1281_CR22","first-page":"92","volume":"1","author":"SR Mueller","year":"2021","unstructured":"Mueller SR, Glanz JM, Nguyen AP, Stowell M, Koester S, Rinehart DJ, et al. Restrictive opioid prescribing policies and evolving risk environments: a qualitative study of the perspectives of patients who experienced an accidental opioid overdose. Int J Drug Policy. 2021;1:92.","journal-title":"Int J Drug Policy"},{"key":"1281_CR23","doi-asserted-by":"crossref","unstructured":"Olfson M, Waidmann T, King M, Pancini V, Schoenbaum M. Population-based opioid prescribing and overdose deaths in the USA: an observational study. J Gen Intern Med. 2022;38(2):390\u20138.","DOI":"10.1007\/s11606-022-07686-z"},{"key":"1281_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.drugalcdep.2014.05.018","volume":"142","author":"B Larance","year":"2014","unstructured":"Larance B, Carragher N, Mattick RP, Lintzeris N, Ali R, Degenhardt L. A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses? Drug Alcohol Depend. 2014;142:46\u201355.","journal-title":"Drug Alcohol Depend"},{"key":"1281_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jclinepi.2017.01.014","volume":"90","author":"VA Welch","year":"2017","unstructured":"Welch VA, Akl EA, Guyatt G, Pottie K, Eslava-Schmalbach J, Ansari MT, et al. GRADE equity guidelines 1: considering health equity in GRADE guideline development: introduction and rationale. J Clin Epidemiol. 2017;90:59\u201367.","journal-title":"J Clin Epidemiol"},{"key":"1281_CR26","doi-asserted-by":"publisher","first-page":"108399","DOI":"10.1016\/j.jsat.2021.108399","volume":"127","author":"JC Marsh","year":"2021","unstructured":"Marsh JC, Amaro H, Kong Y, Khachikian T, Guerrero E. Gender disparities in access and retention in outpatient methadone treatment for opioid use disorder in low-income urban communities. J Subst Abuse Treat. 2021;127:108399.","journal-title":"J Subst Abuse Treat"},{"key":"1281_CR27","unstructured":"Whitehead M, Dahlgren G. Concepts and principles for tackling social inequities in health: Levelling Up Part 1. WHO Collaborating Centre for Policy Research on Social Determinants of Health, University of Liverpool; 2007 p. 45. (Studies on social and economic determinants of population health, No. 2)."},{"issue":"3","key":"1281_CR28","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1057\/s41285-017-0053-2","volume":"16","author":"M Ryvicker","year":"2018","unstructured":"Ryvicker M. A conceptual framework for examining healthcare access and navigation: a behavioral-ecological perspective. Soc Theory Health. 2018;16(3):224\u201340.","journal-title":"Soc Theory Health"},{"issue":"3","key":"1281_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/02791072.2009.10400539","volume":"41","author":"HS Reisinger","year":"2009","unstructured":"Reisinger HS, Schwartz RP, Mitchell SG, Peterson JA, Kelly SM, O\u2019Grady KE, et al. Premature discharge from methadone treatment: patient perspectives. J Psychoactive Drugs. 2009;41(3):285\u201396.","journal-title":"J Psychoactive Drugs"},{"key":"1281_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2019.05.002","volume":"103","author":"N Krawczyk","year":"2019","unstructured":"Krawczyk N, Buresh M, Gordon MS, Blue TR, Fingerhood MI, Agus D. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: addressing a critical care gap. J Subst Abuse Treat. 2019;103:1\u20138.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"1281_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13012-019-0861-y","volume":"14","author":"EN Woodward","year":"2019","unstructured":"Woodward EN, Matthieu MM, Uchendu US, Rogal S, Kirchner JE. The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment. Implement Sci. 2019;14(1):26.","journal-title":"Implement Sci"},{"issue":"1","key":"1281_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13012-022-01189-5","volume":"17","author":"AD Kerkhoff","year":"2022","unstructured":"Kerkhoff AD, Farrand E, Marquez C, Cattamanchi A, Handley MA. Addressing health disparities through implementation science\u2014a need to integrate an equity lens from the outset. Implement Sci. 2022;17(1):13.","journal-title":"Implement Sci"},{"issue":"1","key":"1281_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12875-020-01107-y","volume":"21","author":"L Huddlestone","year":"2020","unstructured":"Huddlestone L, Turner J, Eborall H, Hudson N, Davies M, Martin G. Application of normalisation process theory in understanding implementation processes in primary care settings in the UK: a systematic review. BMC Fam Pract. 2020;21(1):52.","journal-title":"BMC Fam Pract"},{"issue":"1","key":"1281_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12954-021-00582-5","volume":"19","author":"T Parkes","year":"2022","unstructured":"Parkes T, Matheson C, Carver H, Foster R, Budd J, Liddell D, et al. Assessing the feasibility, acceptability and accessibility of a peer-delivered intervention to reduce harm and improve the well-being of people who experience homelessness with problem substance use: the SHARPS study. Harm Reduct J. 2022;19(1):10.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1281_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13012-022-01191-x","volume":"17","author":"CR May","year":"2022","unstructured":"May CR, Albers B, Bracher M, Finch TL, Gilbert A, Girling M, et al. Translational framework for implementation evaluation and research: a normalisation process theory coding manual for qualitative research and instrument development. Implement Sci. 2022;17(1):19.","journal-title":"Implement Sci"},{"key":"1281_CR36","doi-asserted-by":"crossref","unstructured":"Fraser S, Valentine K. Substance and substitution: methadone subjects in liberal societies. London: Palgrave Macmillan; 2008.","DOI":"10.1057\/9780230582569"},{"issue":"1","key":"1281_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13012-021-01177-1","volume":"17","author":"G Parker","year":"2022","unstructured":"Parker G, Shahid N, Rappon T, Kastner M, Born K, Berta W. Using theories and frameworks to understand how to reduce low-value healthcare: a scoping review. Implement Sci. 2022;17(1):6.","journal-title":"Implement Sci"},{"key":"1281_CR38","doi-asserted-by":"publisher","unstructured":"Conway A, Treloar C, Crawford S, Grebely J, Marshall AD. People engaged in opioid agonist treatment as a counterpublic during the COVID-19 pandemic in Australia: A qualitative study. Drug Alcohol Rev. 2023; 42(1):203\u201312. https:\/\/doi.org\/10.1111\/dar.13531.","DOI":"10.1111\/dar.13531"},{"key":"1281_CR39","doi-asserted-by":"publisher","first-page":"103998","DOI":"10.1016\/j.drugpo.2023.103998","volume":"114","author":"A Conway","year":"2023","unstructured":"Conway A, Treloar C, Crawford S, Degenhardt L, Dore GJ, Farrell M, et al. \u201cYou\u2019ll come in and dose even in a global pandemic\u201d: a qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic. Int J Drug Policy. 2023;114:103998.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1281_CR40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/0735275112457914","volume":"30","author":"S Timmermans","year":"2012","unstructured":"Timmermans S, Tavory I. Theory construction in qualitative research: from grounded theory to abductive analysis. Sociol Theory. 2012;30(3):167\u201386.","journal-title":"Sociol Theory"},{"issue":"3","key":"1281_CR41","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/add.15168","volume":"116","author":"L Geddes","year":"2021","unstructured":"Geddes L, Iversen J, Wand H, Maher L. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia. Addiction. 2021;116(3):525\u201335.","journal-title":"Addiction"},{"issue":"7","key":"1281_CR42","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1176\/appi.ps.201700363","volume":"69","author":"A Manhapra","year":"2018","unstructured":"Manhapra A, Agbese E, Leslie DL, Rosenheck RA. Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults. Psychiatr Serv. 2018;69(7):768\u201376.","journal-title":"Psychiatr Serv"},{"issue":"5","key":"1281_CR43","doi-asserted-by":"publisher","first-page":"e0232086","DOI":"10.1371\/journal.pone.0232086","volume":"15","author":"AM O\u2019Connor","year":"2020","unstructured":"O\u2019Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: a systematic review. Latkin CA, editor. PLoS One. 2020;15(5):e0232086.","journal-title":"PLoS One"},{"key":"1281_CR44","doi-asserted-by":"crossref","first-page":"117822181668508","DOI":"10.1177\/1178221816685087","volume":"11","author":"J Woo","year":"2017","unstructured":"Woo J, Bhalerao A, Bawor M, Bhatt M, Dennis B, Mouravska N, et al. \u201c Don \u2019 t judge a book by its cover \u201d: a qualitative study of methadone patients \u2019 experiences of stigma. Subst Abuse Res Treat. 2017;11:1178221816685087.","journal-title":"Subst Abuse Res Treat"},{"key":"1281_CR45","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.socscimed.2015.04.008","volume":"133","author":"R McNeil","year":"2015","unstructured":"McNeil R, Kerr T, Anderson S, Maher L, Keewatin C, Milloy MJ, et al. Negotiating structural vulnerability following regulatory changes to a provincial methadone program in Vancouver, Canada: a qualitative study. Soc Sci Med. 2015;133:168\u201376.","journal-title":"Soc Sci Med"},{"issue":"12","key":"1281_CR46","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1176\/appi.ps.202000226","volume":"71","author":"Y Bao","year":"2020","unstructured":"Bao Y, Williams AR, Schackman BR. COVID-19 Could Change the Way We Respond to the Opioid Crisis\u2014for the Better. Psychiatr Serv. 2020;71(12):1214\u20135.","journal-title":"Psychiatr Serv"},{"issue":"112","key":"1281_CR47","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.2105\/AJPH.2022.306796","volume":"1","author":"J Friedman","year":"2022","unstructured":"Friedman J, Calder\u00f3n-Villarreal A, Adame RC, Abramovitz D, Rafful C, Rangel G, et al. An Ethnographic Assessment of COVID-19-Related Changes to the Risk Environment for People Who Use Drugs in Tijuana. Mexico Am J Public Health. 2022;1(112):S199-205.","journal-title":"Mexico Am J Public Health"},{"key":"1281_CR48","doi-asserted-by":"publisher","first-page":"108374","DOI":"10.1016\/j.jsat.2021.108374","volume":"129","author":"C Russell","year":"2021","unstructured":"Russell C, Ali F, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): a national qualitative study. J Subst Abuse Treat. 2021;129:108374.","journal-title":"J Subst Abuse Treat"},{"key":"1281_CR49","first-page":"1","volume-title":"Interim guidance for the delivery of medication assisted treatment of opioid dependence in response to COVID-19: a national response","author":"N Lintzeris","year":"2020","unstructured":"Lintzeris N, Hayes V, Arunogiri S. Interim guidance for the delivery of medication assisted treatment of opioid dependence in response to COVID-19: a national response. 2020. p. 1\u201318."},{"key":"1281_CR50","doi-asserted-by":"publisher","first-page":"102964","DOI":"10.1016\/j.drugpo.2020.102964","volume":"86","author":"AD Marshall","year":"2020","unstructured":"Marshall AD, Hopwood M, Grebely J, Treloar C. Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: identified challenges for widespread implementation. Int J Drug Policy. 2020;86:102964.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1281_CR51","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.drugalcdep.2013.07.023","volume":"133","author":"C Treloar","year":"2013","unstructured":"Treloar C, Rance J, Grebely J, Dore GJ. Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales. Australia Drug Alcohol Depend. 2013;133(2):529\u201334.","journal-title":"Australia Drug Alcohol Depend"},{"issue":"6","key":"1281_CR52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1371\/journal.pmed.1003266","volume":"17","author":"T Greenhalgh","year":"2020","unstructured":"Greenhalgh T. Will COVID-19 be evidence-based medicine\u2019s nemesis? PLoS Med. 2020;17(6):4\u20137.","journal-title":"PLoS Med"},{"issue":"3","key":"1281_CR53","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1332\/174426420X15913559981103","volume":"16","author":"K Lancaster","year":"2020","unstructured":"Lancaster K, Rhodes T, Rosengarten M. Making evidence and policy in public health emergencies: lessons from COVID-19 for adaptive evidence-making and intervention. Evid Policy. 2020;16(3):477\u201390.","journal-title":"Evid Policy"},{"issue":"April","key":"1281_CR54","doi-asserted-by":"publisher","first-page":"108449","DOI":"10.1016\/j.jsat.2021.108449","volume":"131","author":"S Brothers","year":"2021","unstructured":"Brothers S, Viera A, Heimer R. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19. J Subst Abuse Treat. 2021;131(April):108449.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"1281_CR55","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13011-019-0227-0","volume":"14","author":"K Marchand","year":"2019","unstructured":"Marchand K, Beaumont S, Westfall J, MacDonald S, Harrison S, Marsh DC, et al. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Subst Abuse Treat Prev Policy. 2019;14(1):37.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"1281_CR56","doi-asserted-by":"crossref","unstructured":"McWilliam CL. Creating Understanding That Cultivates Change. Qual Inq. 1996;2(2):151\u201375.","DOI":"10.1177\/107780049600200202"},{"key":"1281_CR57","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/PROM.S297699","volume":"13","author":"N Sanger","year":"2022","unstructured":"Sanger N, Panesar B, Dennis M, Rosic T, Rodrigues M, Lovell E, et al. The inclusion of patients\u2019 reported outcomes to inform treatment effectiveness measures in opioid use disorder. A Systematic Review. Patient Relat Outcome Meas. 2022;13:113\u201330.","journal-title":"Patient Relat Outcome Meas"},{"key":"1281_CR58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.socscimed.2013.01.031","volume":"83","author":"M Harris","year":"2013","unstructured":"Harris M, Rhodes T, Martin A. Taming systems to create enabling environments for HCV treatment: negotiating trust in the drug and alcohol setting. Soc Sci Med. 2013;83:19\u201326.","journal-title":"Soc Sci Med"},{"issue":"1","key":"1281_CR59","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/17523280701759755","volume":"1","author":"C Treloar","year":"2008","unstructured":"Treloar C, Holt M. Complex vulnerabilities as barriers to treatment for illicit drug users with high prevalence mental health co-morbidities. Ment Health Subst Use. 2008;1(1):84\u201395.","journal-title":"Ment Health Subst Use"},{"issue":"S2","key":"1281_CR60","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.2105\/AJPH.2021.306665","volume":"112","author":"C Simon","year":"2022","unstructured":"Simon C, Vincent L, Coulter A, Salazar Z, Voyles N, Roberts L, et al. The methadone manifesto: treatment experiences and policy recommendations from methadone patient activists. Am J Public Health. 2022;112(S2):S117\u201322.","journal-title":"Am J Public Health"},{"key":"1281_CR61","doi-asserted-by":"publisher","first-page":"108367","DOI":"10.1016\/j.jsat.2021.108367","volume":"127","author":"N Kumar","year":"2021","unstructured":"Kumar N, Oles W, Howell BA, Janmohamed K, Lee ST, Funaro MC, et al. The role of social network support in treatment outcomes for medication for opioid use disorder: a systematic review. J Subst Abuse Treat. 2021;127:108367.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"1281_CR62","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/cpp.2062","volume":"24","author":"SM Gainsbury","year":"2017","unstructured":"Gainsbury SM. Cultural competence in the treatment of addictions: theory, practice and evidence: cultural competence in the treatment of addictions: theory, practice and evidence. Clin Psychol Psychother. 2017;24(4):987\u20131001.","journal-title":"Clin Psychol Psychother"},{"issue":"1","key":"1281_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13722-021-00281-3","volume":"16","author":"XA Levander","year":"2021","unstructured":"Levander XA, Hoffman KA, McIlveen JW, McCarty D, Terashima JP, Korthuis PT. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis. Addict Sci Clin Pract. 2021;16(1):1\u201310.","journal-title":"Addict Sci Clin Pract"},{"key":"1281_CR64","volume-title":"Diffusion of innovations","author":"EM Rogers","year":"2014","unstructured":"Rogers EM. Diffusion of innovations. 5th ed. Place of publication not identified: Free Press; 2014.","edition":"5"},{"issue":"2","key":"1281_CR65","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2307\/2090611","volume":"28","author":"E Katz","year":"1963","unstructured":"Katz E, Levin ML, Hamilton H. Traditions of research on the diffusion of innovation. Am Sociol Rev. 1963;28(2):237.","journal-title":"Am Sociol Rev"},{"issue":"9","key":"1281_CR66","doi-asserted-by":"publisher","first-page":"e008592","DOI":"10.1136\/bmjopen-2015-008592","volume":"5","author":"MJ Johnson","year":"2015","unstructured":"Johnson MJ, May CR. Promoting professional behaviour change in healthcare: what interventions work, and why? A theory-led overview of systematic reviews. BMJ Open. 2015;5(9):e008592.","journal-title":"BMJ Open"},{"issue":"8","key":"1281_CR67","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1111\/add.14198","volume":"113","author":"LM Madden","year":"2018","unstructured":"Madden LM, Farnum SO, Eggert KF, Quanbeck AR, Freeman RM, Ball SA, et al. An investigation of an open-access model for scaling up methadone maintenance treatment: Open access. Addiction. 2018;113(8):1450\u20138.","journal-title":"Addiction"},{"issue":"10","key":"1281_CR68","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.drugpo.2015.01.005","volume":"26","author":"C Treloar","year":"2015","unstructured":"Treloar C, Rance J, Bath N, Everingham H, Micallef M, Day C, et al. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study. Australia Int J Drug Policy. 2015;26(10):992\u20138.","journal-title":"Australia Int J Drug Policy"},{"issue":"1","key":"1281_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-021-00461-z","volume":"18","author":"J Chang","year":"2021","unstructured":"Chang J, Shelly S, Busz M, Stoicescu C, Iryawan AR, Madybaeva D, et al. Peer driven or driven peers? A rapid review of peer involvement of people who use drugs in HIV and harm reduction services in low- and middle-income countries. Harm Reduct J. 2021;18(1):1\u201313.","journal-title":"Harm Reduct J"}],"container-title":["Implementation Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13012-023-01281-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13012-023-01281-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13012-023-01281-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T08:04:36Z","timestamp":1686297876000},"score":1,"resource":{"primary":{"URL":"https:\/\/implementationscience.biomedcentral.com\/articles\/10.1186\/s13012-023-01281-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1281"],"URL":"https:\/\/doi.org\/10.1186\/s13012-023-01281-4","relation":{},"ISSN":["1748-5908"],"issn-type":[{"value":"1748-5908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]},"assertion":[{"value":"6 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Human Research Ethics Committee at the University of New South Wales, Sydney (HREC Ref: HC200459) and the Human Research Ethics Committee at St Vincent\u2019s Hospital, Sydney (HREC Ref: 2020\/ETH02342). Participants provided verbal consent prior to the interview.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CT has received speaker fees from Abbvie and Gilead and has received a research grant from Merck outside the submitted work. SC has received speaker fees from Abbvie outside the submitted work. JG is a consultant\/advisor and has received research grants from AbbVie, Camurus, Cepheid, Gilead, Hologic, Indivior, and Merck outside the submitted work. AC, JH, and ADM declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}